Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model

Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model

ABSTRACT Debate continues as to the role of combination antibiotic therapy for the management of Pseudomonas aeruginosa infections. We studied the extent of bacterial killing by and the emergence of resistance to meropenem and amikacin as monotherapies and as a combination therapy against susceptibl...

Full description

Bibliographic Details
Main Authors:	Minyon L. Avent, Kate L. McCarthy, Fekade B. Sime, Saiyuri Naicker, Aaron J. Heffernan, Steven C. Wallis, David L. Paterson, Jason A. Roberts
Format:	Article
Language:	English
Published:	American Society for Microbiology 2022-06-01
Series:	Microbiology Spectrum
Subjects:	amikacin meropenem Pseudomonas aeruginosa pharmacodynamic hollow fiber infection model
Online Access:	https://journals.asm.org/doi/10.1128/spectrum.00525-22

Similar Items

35: EVALUATING MONO- AND COMBINATION THERAPY OF MEROPENEM AND AMIKACIN AGAINST PSEUDOMONAS AERUGINOSA BACTEREMIA IN THE HOLLOW-FIBER INFECTION MODEL
by: Minyon Avent, Dr, et al.
Published: (2022-11-01)

Metabolomics reveals the mechanism of action of meropenem and amikacin combined in the treatment of Pseudomonas aeruginosa
by: Hai Yang, et al.
Published: (2023-12-01)

Propranolol restores susceptibility of XDR Gram-negative pathogens to meropenem and Meropenem combination has been evaluated with either tigecycline or amikacin
by: Samar S. Mabrouk, et al.
Published: (2023-07-01)

Effect of extended infusion of meropenem and nebulized amikacin on Gram-negative multidrug-resistant ventilator-associated pneumonia
by: Mona Ahmed Ammar, et al.
Published: (2018-01-01)

Assessment of the Ototoxic Effects of Amikacin and Meropenem among Neonates in a Tertiary Government Hospital
by: Edgar Jake A. Agullo, et al.
Published: (2014-12-01)

Comparison of three doses of amikacin on alternate days with a daily dose of meropenem during the same period for the treatment of urinary tract infection with E. coli: a double-blind clinical trial
by: Behzad Mohsenpour, et al.
Published: (2024-01-01)

Successful Treatment of Serious Meningitis Caused by Extremely Carbapenem-Resistant Enterobacter cloacae (MIC≥16mg/L) with i.v. Meropenem and i.v. Amikacin Plus Intraventricular Amikacin
by: He Z, et al.
Published: (2019-12-01)

The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection
by: Yuhang Wang, et al.
Published: (2022-10-01)

Time-dependent pharmacodynamics of amikacin on Mycobacterium abscessus growth and resistance emergence
by: Joy E. Gibson, et al.
Published: (2024-02-01)

Cellulitis with persistent bacteremia caused by Campylobacter lari in a patient with mantle-cell lymphoma
by: Yayoi Miyamatsu, et al.
Published: (2021-01-01)

Effects of Meropenem on Patients with Ventilator-Induced Pneumonia in Intensive Care Unit
by: Taraneh Naghibi, et al.
Published: (2022-11-01)

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
by: Eric Wenzler, et al.
Published: (2020-10-01)

Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients
by: Sonia Luque, et al.
Published: (2021-06-01)

In vitro Pharmacokinetics/Pharmacodynamics Evaluation of Fosfomycin Combined with Amikacin or Colistin against KPC2-Producing Klebsiella pneumoniae
by: Wei Yu, et al.
Published: (2017-06-01)

Initial In Vivo Evaluation of a Novel Amikacin-Deoxycholate Hydrophobic Salt Delivers New Insights on Amikacin Partition in Blood and Tissues
by: Styliani Xiroudaki, et al.
Published: (2021-01-01)

Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Staphylococcus aureus Bacteria in a Hollow Fiber Infection Model
by: Diane C. Broussou, et al.
Published: (2018-03-01)

Developmental Population Pharmacokinetics-Pharmacodynamics of Meropenem in Chinese Neonates and Young Infants: Dosing Recommendations for Late-Onset Sepsis
by: Yue-E Wu, et al.
Published: (2022-12-01)

Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: Are we getting close to the right treatment?
by: Silvia Corcione, et al.
Published: (2020-03-01)

Effects of amikacin, polymyxin-B, and sulbactam combination on the pharmacodynamic indices of mutant selection against multi-drug resistant Acinetobacter baumannii
by: Shixing Zhu, et al.
Published: (2022-10-01)

Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm
by: Mona Shaban E. M. Badawy, et al.
Published: (2023-07-01)

Pharmacodynamic Evaluation of a Single Dose versus a 24-Hour Course of Multiple Doses of Cefazolin for Surgical Prophylaxis
by: Aaron Heffernan, et al.
Published: (2021-05-01)

Population PK/PD modelling of meropenem in preterm newborns based on therapeutic drug monitoring data
by: Sergey Zyryanov, et al.
Published: (2023-03-01)

Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant <i>Acinetobacter baumannii</i> Isolates in a Hollow-Fibre Infection Model
by: Sazlyna Mohd Sazlly Lim, et al.
Published: (2022-11-01)

Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study
by: Hui-Ying Zhao, et al.
Published: (2017-01-01)

Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
by: Guoliang Deng, et al.
Published: (2023-03-01)

Population Pharmacokinetics of Amikacin in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation
by: Claire Pressiat, et al.
Published: (2022-01-01)

Growth kinetics of multiple Acinetobacter baumannii resistotype after meropenem-based antibiotic combination exposure [version 2; peer review: 2 approved]
by: Erizka Rivani, et al.
Published: (2022-11-01)

Evaluation of Current Amikacin Dosing Recommendations and Development of an Interactive Nomogram: The Role of Albumin
by: Jonás Samuel Pérez-Blanco, et al.
Published: (2021-02-01)

A pharmacodynamic strategy to optimize empirical antibiotic therapy for gram-negative bacteria in a Brazilian Intensive Care Unit
by: Carlos R.V. Kiffer, et al.

Intrathecal use of amikacin: a case report
by: L. Barrou, et al.

Clinical Pharmacokinetics of Amikacin in Neonates
by: Gian Maria Pacifici, et al.
Published: (2017-02-01)

Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis
by: Renata Černá Pařízková, et al.
Published: (2021-07-01)

Prevalence of Klebsiella pneumoniae carbapenemase - and New Delhi metallo-beta-lactamase-positive K. pneumoniae in Sergipe, Brazil, and combination therapy as a potential treatment option
by: Roberto Vivas, et al.
Published: (2020-05-01)

Improving the efficacy for meropenem therapy requires a high probability of target attainment in critically ill infants and children
by: Zeming Wang, et al.
Published: (2022-10-01)

Comparative Study between Combined Intravenous and Nebulized Amikacin versus Intravenous Amikacin Alone for Treatment of Ventilator Associated Pneumonia
by: Sameh Seyam, et al.
Published: (2022-06-01)

The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant Acinetobacter baumannii
by: Jiayuan Zhang, et al.
Published: (2022-11-01)

Protective effect of creatine on amikacin-induced ototoxicity
by: Emre Apaydın, et al.
Published: (2022-09-01)

Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools
by: Ferdinand Anton Weinelt, et al.
Published: (2022-06-01)

The Direction of the Antibacterial Effect of Rutin Hydrate and Amikacin
by: Maria Miklasińska-Majdanik, et al.
Published: (2023-09-01)

Effect of mannitol on the pharmacokinetics of amikacin in wistar rats
by: Hugo Juárez Olguín, et al.
Published: (2009-08-01)